Aster Insights has announced three upcoming presentations at the 2023 American Society of Hematology (ASH) Annual Meeting, which will be held from December 9-12 in San Diego, CA. Three ORIEN scientists from Moffitt Cancer Center will present key findings on multiple myeloma using data from Aster Avatar, including a longitudinal study of response to anti-BCMA CAR-T treatment.
“ASH is a unique opportunity to demonstrate the impactful discoveries resulting from ORIEN and Aster Insights’ discovery solutions,” said Anand Shah, MD, CEO of Aster Insights. “This year, we are proud to showcase our collaborative work with Moffitt Cancer Center’s scientists that continues to push the envelope of multiple myeloma research and patient care.”
The presentations will take place on Saturday, December 9, and Sunday, December 10.
Ex Vivo Mathematical Myeloma Advisor (EMMA) – a Clinical, Molecular, and Phenotypic Platform to Tailor Personalized Therapeutic Strategies for Multiple Myeloma
- Abstract #2280
- Presenter: Rafael Renatino-Canevarolo, PhD
- Time: Saturday, December 9, 5:30-7:30 p.m.
- More details about this abstract
Selinexor Disrupts Epigenetic Programming and Modulates Immunogenicity in Multiple Myeloma
- Abstract #3301
- Presenter: Praneeth Reddy Sudalagunta, PhD
- Time: Sunday, December 10, 6:00-8:00 p.m.
- More details about this abstract
Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease
- Abstract #3304
- Presenter: Ciara L. Freeman, PhD, MSc, FRCPC, MRCP
- Time: Sunday, December 10, 6:00-8:00 p.m.
- More details about this abstract
Read more in the full press release.